References
  1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.
  2. Cipolla-Neto J, Amaral FGD. Melatonin as a Hormone: New Physiological and Clinical Insights. Endocr Rev. 2018 Dec 1;39(6):990-1028. doi: 10.1210/er.2018-00084. PMID: 30215696.
  3. M.Singh, H.R. Jadhav. Melatonin: functions and ligands. Drug Discov. Today. 2014;19(9):1410-1418.
  4. Claustrat B, Leston J. Melatonin: Physiological effects in humans. Neurochirurgie. 2015 Apr-Jun;61(2-3):77-84. doi: 10.1016/j.neuchi.2015.03.002. Epub 2015 Apr 20. PMID: 25908646.
  5. de Weerth C, Zijl RH, Buitelaar JK. Development of cortisol circadian rhythm in infancy. Early Hum Dev. 2003 Aug;73(1-2):39-52. doi: 10.1016/s0378-3782(03)00074-4. PMID: 12932892.
  6. Law R, Hucklebridge F, Thorn L, Evans P, Clow A. State variation in the cortisol awakening response. Stress. 2013 Sep;16(5):483-92. doi: 10.3109/10253890.2013.817552. Epub 2013 Jul 29. PMID: 23805796.
  7. Pierre K, Rao RT, Hartmanshenn C, Androulakis IP. Modeling the Influence of Seasonal Differences in the HPA Axis on Synchronization of the Circadian Clock and Cell Cycle. Endocrinology. 2018 Apr 1;159(4):1808-1826. doi: 10.1210/en.2017-03226. PMID: 29444258; PMCID: PMC6044315.
  8. Gómez-Acebo I, Dierssen-Sotos T, Papantoniou K, García-Unzueta MT, Santos-Benito MF, Llorca J. Association between exposure to rotating night shift versus day shift using levels of 6-sulfatoxymelatonin and cortisol and other sex hormones in women. Chronobiol Int. 2015 Feb;32(1):128-35. doi: 10.3109/07420528.2014.958494. Epub 2014 Sep 12. PMID: 25216206.
  9. DeSantis AS, DiezRoux AV, Hajat A, Aiello AE, Golden SH, Jenny NS, Seeman TE, Shea S. Associations of salivary cortisol levels with inflammatory markers: the Multi-Ethnic Study of Atherosclerosis. Psychoneuroendocrinology. 2012 Jul;37(7):1009-18. doi: 10.1016/j.psyneuen.2011.11.009. Epub 2011 Dec 16. PMID: 22178583; PMCID: PMC3358540.
  10. Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, Li HB. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921. doi: 10.18632/oncotarget.16379. PMID: 28415828; PMCID: PMC5503661.
  11. Talib WH. Melatonin and Cancer Hallmarks. Molecules. 2018 Feb 26;23(3):518. doi: 10.3390/molecules23030518. PMID: 29495398; PMCID: PMC6017729.
  12. Kubatka P, Zubor P, Busselberg D, Kwon TK, Adamek M, Petrovic D, Opatrilova R, Gazdikova K, Caprnda M, Rodrigo L, Danko J, Kruzliak P. Melatonin and breast cancer: Evidences from preclinical and human studies. Crit Rev Oncol Hematol. 2018 Feb;122:133-143. doi: 10.1016/j.critrevonc.2017.12.018. Epub 2017 Dec 29. PMID: 29458781.
  13. Veiga ECA, Simões R, Valenti VE, Cipolla-Neto J, Abreu LC, Barros EPM, Sorpreso ICE, Baracat MCP, Baracat EC, Soares Junior JM. Repercussions of melatonin on the risk of breast cancer: a systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2019 Jun 3;65(5):699-705. doi: 10.1590/1806-9282.65.5.699. PMID: 31166448.
  14. Mayo JC, Hevia D, Quiros-Gonzalez I, Rodriguez-Garcia A, Gonzalez-Menendez P, Cepas V, Gonzalez-Pola I, Sainz RM. IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer. J Pineal Res. 2017 Jan;62(1). doi: 10.1111/jpi.12373. Epub 2016 Nov 9. PMID: 27736013.
  15. Calastretti A, Gatti G, Lucini V, Dugnani S, Canti G, Scaglione F, Bevilacqua A. Melatonin Analogue Antiproliferative and Cytotoxic Effects on Human Prostate Cancer Cells. Int J Mol Sci. 2018 May 18;19(5):1505. doi: 10.3390/ijms19051505. PMID: 29783631; PMCID: PMC5983593.
  16. Calastretti A, Gatti G, Lucini V, Dugnani S, Canti G, Scaglione F, Bevilacqua A. Melatonin Analogue Antiproliferative and Cytotoxic Effects on Human Prostate Cancer Cells. Int J Mol Sci. 2018 May 18;19(5):1505. doi: 10.3390/ijms19051505. PMID: 29783631; PMCID: PMC5983593.
  17. Calastretti A, Gatti G, Lucini V, Dugnani S, Canti G, Scaglione F, Bevilacqua A. Melatonin Analogue Antiproliferative and Cytotoxic Effects on Human Prostate Cancer Cells. Int J Mol Sci. 2018 May 18;19(5):1505. doi: 10.3390/ijms19051505. PMID: 29783631; PMCID: PMC5983593.
  18. Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008 Jan;101(1):5-10. doi: 10.1111/j.1464-410X.2007.07138.x. Epub 2007 Aug 30. PMID: 17760888.
  19. Rzepka-Migut B, Paprocka J. Melatonin-Measurement Methods and the Factors Modifying the Results. A Systematic Review of the Literature. Int J Environ Res Public Health. 2020 Mar 15;17(6):1916. doi: 10.3390/ijerph17061916. PMID: 32183489; PMCID: PMC7142625.
  20. Xiao WJ, Zhu Y, Zhu Y, Dai B, Ye DW. Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer. World J Urol. 2018 May;36(5):769-774. doi: 10.1007/s00345-018-2183-0. Epub 2018 Jan 25. PMID: 29372356.
  21. Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Flüchter SH. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta. 1992 Aug 31;209(3):153-67. doi: 10.1016/0009-8981(92)90164-l. PMID: 1395046.
  22. Sigurdardottir LG, Markt SC, Rider JR, Haneuse S, Fall K, Schernhammer ES, Tamimi RM, Flynn-Evans E, Batista JL, Launer L, Harris T, Aspelund T, Stampfer MJ, Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir UA, Mucci LA. Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. Eur Urol. 2015 Feb;67(2):191-4. doi: 10.1016/j.eururo.2014.07.008. Epub 2014 Aug 5. PMID: 25107635; PMCID: PMC4318783.
  23. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem. 2002 Feb;2(2):113-32. doi: 10.2174/1568026023394407. PMID: 11899096.
  24. Reiter RJ, Tan DX, Erren TC, Fuentes-Broto L, Paredes SD. Light-mediated perturbations of circadian timing and cancer risk: a mechanistic analysis. Integr Cancer Ther. 2009 Dec;8(4):354-60. doi: 10.1177/1534735409352026. PMID: 20042411.
  25. Pariollaud M, Lamia KA. Cancer in the Fourth Dimension: What Is the Impact of Circadian Disruption? Cancer Discov. 2020 Oct;10(10):1455-1464. doi: 10.1158/2159-8290.CD-20-0413. Epub 2020 Sep 15. PMID: 32934020; PMCID: PMC7541588.
  26. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, Sauer LA, Rivera-Bermudez MA, Dubocovich ML, Jasser SA, Lynch DT, Rollag MD, Zalatan F. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res. 2005 Dec 1;65(23):11174-84. doi: 10.1158/0008-5472.CAN-05-1945. PMID: 16322268.
  27. Blask DE, Dauchy RT, Brainard GC, Hanifin JP. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. Integr Cancer Ther. 2009 Dec;8(4):347-53. doi: 10.1177/1534735409352320. PMID: 20042410.
  28. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res. 2010 Aug;49(1):60-8. doi: 10.1111/j.1600-079X.2010.00767.x. Epub 2010 May 27. PMID: 20524973; PMCID: PMC3158680.
  29. Jung-Hynes B, Schmit TL, Reagan-Shaw SR, Siddiqui IA, Mukhtar H, Ahmad N. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res. 2011 Mar;50(2):140-9. doi: 10.1111/j.1600-079X.2010.00823.x. Epub 2010 Nov 9. PMID: 21062352; PMCID: PMC3052633.
  30. Cole TJ, Short KL, Hooper SB. The science of steroids. Semin Fetal Neonatal Med. 2019 Jun;24(3):170-175. doi: 10.1016/j.siny.2019.05.005. Epub 2019 May 23. PMID: 31147162.
  31. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019 Jul-Sep;18(3):121-126. doi: 10.4103/aam.aam_56_18. PMID: 31417011; PMCID: PMC6704802.
  32. Mirick DK, Bhatti P, Chen C, Nordt F, Stanczyk FZ, Davis S. Night shift work and levels of 6-sulfatoxymelatonin and cortisol in men. Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1079-87. doi: 10.1158/1055-9965.EPI-12-1377. Epub 2013 Apr 5. PMID: 23563887; PMCID: PMC4772962.
  33. Wetterbuerg L, Beck-Friis J, Aperia B, Petterson U. Melatonin/cortisol ratio in depression. Lancet. 1979 Dec 22-29;2(8156-8157):1361. doi: 10.1016/s0140-6736(79)92837-x. PMID: 92692.
  34. Vezyraki P, Vlachaki A, Baltogiannis D, Batistatou A, Tsampalas S, V Simos Y, Kaltsas A, Pappas P, Dounousi E, Ragos V, Tsiambas E, Peschos D. Impact of total PSA and percent free PSA in the differentiation of prostate disease: a retrospective comparative study implicating neoplastic and non-neoplastic entities. J BUON. 2019 Sep-Oct;24(5):2107-2113. PMID: 31786882.
  35. Fu S, Zhang X, Niu Y, Wang RT. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia. Asian Pac J Cancer Prev. 2018 Mar 27;19(3):699-702. doi: 10.22034/APJCP.2018.19.3.699. PMID: 29580043; PMCID: PMC5980844.
  36. Costa P, Ben Naoum K, Boukaram M, Wagner L, Louis JF. Hyperplasie bénigne de la prostate (HBP) : prévalence en médecine générale et attitude pratique des médecins généralistes français. Résultats d’une etude réalisée auprès de 17.953 patients [Benign prostatic hyperplasia (BPH): prevalence in general practice and practical approach of French general practitioners. Results of a study based on 17,953 patients]. Prog Urol. 2004 Feb;14(1):33-9. French. PMID: 15098749.
Table 1. Demographic characteristics of all participants.